RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sio Gene Therapies - Stock

Sio Gene Therapies Stocks 2024

Sio Gene Therapies Stocks

73.21 M

Ticker

SIOX

ISIN

US8293991043

WKN

A2QHKW

In 2024, Sio Gene Therapies had 73.21 M outstanding stocks, a 0% change from the 73.21 M stocks in the previous year.

The Sio Gene Therapies Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2027e73.21
2026e73.21
2025e73.21
2024e73.21
2023e73.21
202273.21
202152.18
202024.81
201916.1
201813.42
201712.39
201611.81
201511.61

Sio Gene Therapies shares outstanding

The number of shares was Sio Gene Therapies in 2023 — This indicates how many shares 73.21 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sio Gene Therapies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sio Gene Therapies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sio Gene Therapies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sio Gene Therapies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sio Gene Therapies Aktienanalyse

What does Sio Gene Therapies do?

Sio Gene Therapies Inc. is a biopharmaceutical company focused on developing gene therapies for rare genetic diseases. The company was founded in 2000 by a team of scientists specializing in the research of gene therapies for the treatment of rare diseases. Sio Gene Therapies' history began with the goal of providing an alternative treatment method for patients with rare diseases. The company focuses on the discovery and development of gene therapies based on the use of vectors to deliver genes into defective cells. The company has focused on diseases such as Huntington's chorea, Parkinson's disease, and rare hereditary diseases. Sio Gene Therapies' business model is designed to develop and market gene therapy as a novel therapy for rare diseases. The company pursues an innovative research program that aims to discover rare diseases and identify genetic mutations associated with these diseases. Sio Gene Therapies collaborates with leading scientists and research institutions to develop innovative approaches to the treatment of rare genetic diseases. Sio Gene Therapies has several divisions, including a research facility, a development department, and a sales department. Each of these departments plays a crucial role in the development of gene therapies for rare diseases. The research department identifies new target genes for the development of gene therapies, the development department develops and tests vectors for gene therapy, and the sales department works closely with physicians and health authorities to market and make gene therapy available. Sio Gene Therapies has developed a range of products based on gene therapy. This includes Axovant, a gene therapy for the treatment of Parkinson's disease that aims to deliver genes into defective cells. The drug is currently in the clinical testing stage. Peroxysome biogenesis disorder (PBD) is a rare hereditary disease caused by a dysfunction of peroxisomes. The company has already completed initial clinical studies with its product AXO-AAV-CLN6, a gene therapy approach for PBD. The results of these studies are promising, and the company is currently in Phase III of clinical studies. Sio Gene Therapies has achieved several milestones in recent years. In 2017, the company received approval from the U.S. Food and Drug Administration (FDA) for its first gene therapy for the treatment of rare degenerative retinal diseases. In August 2020, the company initiated a Phase III study for the treatment of PBD with AXO-AAV-CLN6. Overall, Sio Gene Therapies has established itself as a successful company in the gene therapy industry and has specialized in the development of gene therapies for rare genetic diseases. The company has made significant progress in the development of gene therapies in recent years and has also received important approvals from the FDA. Through ongoing research and development of new products, the company intends to contribute to the treatment and cure of rare genetic diseases in the future. Sio Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Sio Gene Therapies's Shares Outstanding

Sio Gene Therapies's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Sio Gene Therapies’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Sio Gene Therapies’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Sio Gene Therapies’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Sio Gene Therapies Stock

How many stocks are there of Sio Gene Therapies?

The current number of stocks of Sio Gene Therapies is 73.21 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Sio Gene Therapies are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Sio Gene Therapies evolved in recent years?

The number of shares of Sio Gene Therapies has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Sio Gene Therapies as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Sio Gene Therapies?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Sio Gene Therapies pay?

Over the past 12 months, Sio Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sio Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Sio Gene Therapies?

The current dividend yield of Sio Gene Therapies is .

When does Sio Gene Therapies pay dividends?

Sio Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sio Gene Therapies?

Sio Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Sio Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sio Gene Therapies located?

Sio Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sio Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sio Gene Therapies from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Sio Gene Therapies pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Sio Gene Therapies in the year 2023?

In the year 2023, Sio Gene Therapies distributed 0 USD as dividends.

In which currency does Sio Gene Therapies pay out the dividend?

The dividends of Sio Gene Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sio Gene Therapies

Our stock analysis for Sio Gene Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sio Gene Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.